Health Care · Pharmaceutical Preparations

URGN UroGen Pharma Ltd. SEC Filings & Insider Trading Activity 2026

company
CIK 166824398 filings
Russell 2000

URGN at a glance

UroGen Pharma Ltd. (URGN, SEC CIK 1668243) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), UroGen Pharma Ltd. (URGN) reported revenue of $109.8 million (up 21.4% from FY2024) and a net loss of $153.5 million. Diluted EPS was -$3.19.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding UroGen Pharma Ltd. (URGN) shares worth $451.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Degnan Chris on October 8, 2026 of 2,202 shares at $36.69 per share.
  • In the last 90 days, URGN insiders reported 0 open-market purchases ($0) and 3 open-market sales ($183K) on Form 4, a net sale of $183K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$109.8M
+21.4% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$183K
13F holders
27 funds
$451.3M · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $89.0M vs $27.5M, up $61.5M YoY, driven primarily by Zusduri sales
  • Gross margin 91.6% vs 88.1% YoY, operating margin 9.4% vs negative 99.7%
  • Zusduri strongest growth driver, $61.5M revenue increase; Jelmyto standalone revenue not disclosed
  • Cash and marketable securities $90.5M; operating cash use $93.5M through nine months
  • Pharmakon refinancing provided $67.5M financing cash; management expects funding beyond one year, but may need additional capital

Risk Factors

  • New tariff exposure: 15% U.S. tariff on imported mitomycin for Zusduri, effective September 29, 2026
  • New financing structure: $200.0 million Pharmakon tranche refinanced $125.0 million outstanding debt, with $50.0 million available through June 30, 2027
  • Most material operational risk: TAPI currently sole supplier of commercial mitomycin under April 2026 agreement
  • Regulatory risk: FDA staffing reductions and policy changes could delay UGN-103 review, targeting June 14, 2027 action date
  • Near-term market risk: Zusduri commercialization depends on physician adoption as the first FDA-approved nonsurgical treatment for recurrent low-grade intermediate-risk NMIBC

AI summary of the URGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • ZUSDURI revenue $68.0M, up 35% quarter-over-quarter, with 331 repeat prescribers supporting commercial adoption
  • FDA accepted UGN-103 NDA, with PDUFA target date June 14, 2027, creating a potential successor and portfolio expansion
Filed Aug 20, 2026Full analysis →

Item 8.01: Other Events

  • Exclusive worldwide option for TumoCure and additional SRGel-based products expands UroGen’s oncology pipeline
  • SRGel platform targets sustained-release delivery, potentially complementing UroGen’s drug-delivery expertise
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • ZUSDURI revenue reached $50.4M, up 73% quarter-over-quarter, signaling rapid launch adoption across 1,444 care sites
  • Repeat prescribers rose to 45% from 40%, supporting improving retention and commercial durability

Item 2.02: Results of Operations and Financial Condition

  • UroGen announced financial results for the quarter ended June 30, 2026
  • Detailed revenue, earnings, cash position and guidance information appears in Exhibit 99.1

AI summaries of URGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for URGN

Don't miss the next URGN filing

  • Alerts as it files. A push when URGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut URGN, by share count.
  • Ask anything. An AI agent that reads every URGN filing and answers with sources.

URGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Degnan ChrisMOct 8, 2026-
Degnan ChrisSellOct 8, 2026$36.69
Degnan ChrisMOct 8, 2026-
Smith Jason DrewSellSep 8, 2026$42.54
Schoenberg MarkSellSep 8, 2026$42.92
Smith Jason DrewMSep 7, 2026-
Schoenberg MarkMSep 7, 2026-
Schoenberg MarkMSep 7, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$82.7M$90.4M$109.8M
Gross Profit-$81.5M$97.3M
Operating Income--$96.8M-$124.9M
Net Income--$126.9M-$153.5M
Gross Margin-90.2%88.7%
Op. Margin--107.1%-113.7%
Net Margin--140.4%-139.8%
Balance Sheet
Total Assets-$285.7M$200.5M
Equity--$8.8M-$105.5M
ROE-1441.3%145.5%
Per Share
EPS-$-2.96$-3.19
Cash Flow
Operating CF--$96.8M-$162.4M
CapEx$194K$295K$289K

Source: XBRL data in UroGen Pharma Ltd. (URGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate URGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
URGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$451.3M
Q2 202627$412.8M
Q1 202624$185.0M
Q4 202525$274.2M
Q3 202524$260.5M
Q2 202525$143.7M
Q1 202519$50.0M
Q4 202416$33.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

URGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Aug 28, 2026--
4Aug 24, 2026--
8-KAug 20, 2026Analysis-
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 10, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
4Jun 24, 2026--
8-KJun 23, 2026Analysis-
4Jun 9, 2026-
8-KJun 2, 2026Analysis
4May 27, 2026-
SC 13GMay 15, 2026-
4May 11, 2026-
10-QMay 6, 2026Analysis

Related Health Care companies

All Health Care →

URGN SEC filings: frequently asked questions

Are URGN insiders buying or selling?

In the last 90 days, UroGen Pharma Ltd. (URGN) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $182,793 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold URGN stock?

As of September 30, 2026, the largest UroGen Pharma Ltd. (URGN) holders among the 13F filers tracked by SignalX were BlackRock ($126.3 million), Morgan Stanley ($88.4 million), D.E. Shaw & Co ($52.2 million), State Street Corp ($39.6 million), Goldman Sachs Group ($34.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was URGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), UroGen Pharma Ltd. (URGN) reported revenue of $109.8 million (up 21.4% from FY2024) and a net loss of $153.5 million. Diluted EPS was -$3.19. The figures come from the XBRL data in the 10-K.

What did URGN report in its latest 8-K?

UroGen Pharma Ltd. (URGN) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest URGN SEC filings?

UroGen Pharma Ltd. (URGN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 9, 2026.

What is URGN's SEC CIK number?

UroGen Pharma Ltd. (URGN)'s SEC Central Index Key (CIK) is 1668243. EDGAR lists every URGN filing under that number.

Ask anything about URGN

The research agent reads URGN's filings, financials, insider trades and 13F holders, then answers with sources.